NASDAQ OMX

Oxford Immunotec Appoints Richard Wenstrup, MD, as Chief Medical Officer

24.7.2017 15:00 | NASDAQ OMX

Dela

OXFORD, United Kingdom and MARLBOROUGH, Mass., July 24, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced the appointment of Richard Wenstrup, MD, as Chief Medical Officer.

Dr. Wenstrup brings to Oxford Immunotec more than 20 years of clinical leadership experience, including over a decade within the diagnostics industry. Most recently, Dr. Wenstrup served as Executive Vice President, Chief Medical Officer, for Myriad Genetics, Inc., where he played a key leadership role and made substantial contributions across the company that helped drive and support a multi-fold increase in revenue over a decade. In addition to building and leading Myriad's clinical and medical affairs teams, Dr. Wenstrup was actively involved in the company's product development, M&A, and in-licensing activities. He also previously served as Chief Medical Officer for Myriad Genetic Laboratories, Inc.

"We are extremely pleased to welcome Rick to the team during this exciting time at Oxford Immunotec," said CEO, Dr. Peter Wrighton-Smith. "Rick's extensive leadership experience and the depth and breadth of his clinical, scientific, and commercial expertise will be immensely valuable as we continue to grow our core tuberculosis franchise and launch products into the new markets of tick-borne diseases, blood screening and transplantation."

Prior to joining Myriad Genetics, Dr. Wenstrup served as a tenured Professor of Pediatrics (Human Genetics) at Cincinnati Children's Hospital Medical Center and as a tenured Professor of Biomedical Engineering at the University of Cincinnati. During his time in academia, Dr. Wenstrup was principal investigator on multiple research grants from the National Institutes of Health (NIH) and the FDA Orphan Products Grant Program. He also served as a standing member of NIH review committees and on the scientific advisory boards of several disease-related foundations. Dr. Wenstrup was the founding director of the Molecular Diagnostics Laboratory at Cincinnati Children's Hospital and co-founder of Assurex Health, Inc., now a subsidiary of Myriad Genetics, Inc.

About Oxford Immunotec

Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions.  The Company's first product is the T-SPOT®.TB test, which is used to test for tuberculosis infection.  The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China.  The Company's second product line is a range of assays for tick-borne diseases, such as Lyme disease, obtained through the acquisitions of Imugen and Immunetics.  Also obtained through the acquisitions is the Company's third product line focused on screening for Babesia in donated blood, for which the Company is currently seeking FDA licensure.  The T-SPOT.CMV test and the T-SPOT.PRT test are pipeline products as part of the Company's fourth intended product line focused on the transplantation market.  In addition to these four product lines, the Company has additional active development programs in other immune-regulated conditions.  The Company is headquartered near Oxford, U.K. and in Marlborough, Mass.  Additional information can be found at www.oxfordimmunotec.com.

T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.  Immunetics is a trademark of Immunetics, Inc.

CONTACTS:

For Media and Investor Inquiries: 
Karen Koski
Head of Strategy and Investor Relations
Oxford Immunotec
Tel: +1 (508) 556-1377
kkoski@oxfordimmunotec.com

Mark Klausner
Westwicke Partners
Tel: +1 (443) 213-0501
oxfordimmunotec@westwicke.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Oxford Immunotec via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.

Senaste pressmeddelandena från NASDAQ OMX

ATTO ThunderLink® enables VMware® ESXi(TM) for Mac Pro®24.8.2017 10:00Pressmeddelande

AMHERST, N.Y., Aug.  24, 2017  (GLOBE NEWSWIRE) -- ATTO Technology, Inc., a global leader of storage, network connectivity and infrastructure solutions for data-intensive computing environments for nearly 30 years, today is proud to announce their 16Gb and 8Gb Fibre Channel ThunderLink® Thunderbolt(TM) devices have achieved VMware Ready(TM) status for ESXi(TM). ATTO ThunderLink devices are the only purpose built Thunderbolt product designed to connect virtualized Mac hardware to 16Gb and 8Gb Fibre Channel storage solutions within VMware® VSphere environments. This provides a new and efficient solution for Apple technologies application development and testing environments, virtual desktop infrastructure and cloud hosting or shared private cloud. "By utilizing an ATTO ThunderLink in a VMware environment users can now take advantage of a one of a kind solution to bring virtualized Macs into test and development environments," said Tom Kolniak, Senior Director of

Karolinska Development - Delårsrapport för januari - juni 2017, inbjudan till telefonkonferens och webbpresentation24.8.2017 08:00Pressmeddelande

STOCKHOLM den 24 augusti 2017. Karolinska Development AB (Nasdaq Stockholm: KDEV) kommer att offentliggöra delårsrapporten för januari - juni 2017 efter att marknaden har stängt den 29 augusti 2017. Bolaget kommer även att hålla en telefonkonferens och webbpresentation den 30 augusti klockan 14.00 CEST. Vänligen ring in på något av följande telefonnummer några minuter före telefonkonferensens start: Från Sverige: +46 (0) 8 505 564 74 Från USA: +1 855 753 22 30 Från Storbritannien: +44 (0) 20 336 453 74 Webbpresentationen kan samtidigt nås från: https://edge.media-server.com/m6/p/7zkrjqvs Presentatör: Viktor Drvota, VD. För ytterligare information, vänligen kontakta : Viktor Drvota, VD, Karolinska Development AB Tel: +46 73 982 52 02, e-mail: viktor.drvota@karoli

Karolinska Development - Interim Report (January-June 2017) - Invitation to conference call and webcast24.8.2017 08:00Pressmeddelande

STOCKHOLM - August 24, 2017. Karolinska Development AB (Nasdaq Stockholm: KDEV) will publish its Interim Report - January-June 2017 on August 29, 2017 after market closure. The company will also host a conference call and an online presentation on August 30, at 2 pm CEST. Please dial in at one of the following numbers a few minutes before the start of the conference call: The Company will host a conference call on August 30, 2017 at 2 pm CEST. Please dial in at one of the following numbers a few minutes before the start of the conference call: From Sweden: +46 (0) 8 505 564 74 From the US: +1 855 753 22 30 From the UK: +44 (0) 20 336 453 74 The presentation will also be webcast and can be accessed from the following web address: https://edge.media-server.com/m6/p/7zkrjqvs Host: Viktor Drvota, CEO. For further information, please contact: Viktor Drvota, CEO, Karolinska Dev

PayByPhone Appoints Francis Dupuis as new CEO24.8.2017 01:14Pressmeddelande

VANCOUVER, British Columbia, Aug. 23, 2017 (GLOBE NEWSWIRE) -- PayByPhone, the global leader in mobile parking payments, today announced that it has appointed Francis Dupuis as President and Chief Executive Officer effective August 23rd, 2017. Kush Parikh, former President and CEO, has stepped down from the role after his successful 3.5-year term with the business. During his time at PayByPhone, Kush led the business to profitability, established a strong focus on end customers and was pivotal in its ground-breaking sale to Volkswagen Financial Services.  "With more than 20 years of experience in the software industry and a deep product background, Francis is exactly the kind of leader we need to further grow and innovate in the parking market on an international scale," said Stefan Imme, Head of M&A and Investment Management at Volkswagen Financial Services AG. Francis, a long-standing member of the executive team at PayByPhone, takes the reins at a

Kommuniké från extra bolagsstämma i LeoVegas, 23 augusti 201723.8.2017 16:34Pressmeddelande

Extra bolagsstämma i LeoVegas AB (publ) ("LeoVegas" eller "Bolaget") hölls idag den 23 augusti 2017 varvid aktieägarna fattade följande beslut. Beslut om incitamentsprogram till anställda Stämman beslutade enhälligt, i enlighet med styrelsens förslag, att emittera högst 1 000 000 teckningsoptioner med avvikelse från aktieägarnas företrädesrätt till följd varav Bolagets aktiekapital kan komma att öka med högst 12 000,000022 euro. Teckningsoptionerna medför rätt till nyteckning av aktier i Bolaget. Incitamentsprogrammet ersätter det från årsstämman den 17 maj 2017 beslutade programmet i vilket samtliga teckningsoptioner makulerats efter beslut av styrelsen den 23 juli 2017 som registrerades hos Bolagsverket den 26 juli 2017. Rätt att teckna teckningsoptionerna ska tillkomma Gears of Leo AB ("Dotterbolaget") med rätt och skyldighet att, vid ett eller flera tillfäl

Announcement from LeoVegas's extra general meeting, 23 August 201723.8.2017 16:34Pressmeddelande

The extra general meeting ("EGM") of LeoVegas AB (publ) ("LeoVegas" or the "Company") was held today on 23 August 2017 and the following resolutions were passed. Resolution regarding incentive program for employees The EGM resolved unanimously, in accordance with the board of directors' proposal to issue a maximum of 1,000,000 warrants, with deviation from the shareholders preferential rights, which may result in a maximum increase in the Company's share capital of EUR 12,000.000022. The warrants shall entitle to subscription of new shares in the Company. The incentive program replaces the program resolved on by the annual general meeting held on 17 May 2017 in which all issued warrants have been cancelled in accordance with the board of directors resolution on 23 July 2017 which was registered with the Swedish Companies registration Office on 26 July 2017. The

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum